Shots:
- The P-III ASCEND program includes 5 studies i.e ASCEND-ND, D, ID, NHQ & TD studies evaluating efficacy & safety of daprodustat vs ESA in ~8,000 patients with anemia due to CKD for ~ 3.75yrs.
- The program met its 1EPs in 5 studies i.e improvement in Hgb levels in untreated patients and maintaining Hgb levels in patients treated with ESA. Therapy was generally well-tolerated in both non-dialysis & dialysis patients, AEs were similar b/w treatment groups
- The co-primary EPs of ASCEND-ND & ASCEND-D studies in non-dialysis and dialysis patients showed that the therapy was non-inferior compared to an ESA in the risk of MACE. The therapy is currently approved as Duvroq for renal anemia in Japan
Click here to read the full press release/ article | Ref: GSK | Image: The Economic Times
The post GSK Reports Results of Daprodustat in P-III ASCEND Program for the Treatment of Anemia due to Chronic Kidney Disease first appeared on PharmaShots.
